Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

The results suggest that by using an antibody they were able to block the interaction between APOE proteins and LILRB4 ...

Interestingly, those participants who carried the genetic risk factor, APOE-4, were no more likely to show cognitive decline linked to HSV-1 antibodies. The findings contradict previous research ...

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...